Core Insights - eXoZymes Inc. has successfully achieved a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process [1] - The scale-up utilizes a proprietary exozyme-based, cell-free biomanufacturing platform with a conversion level exceeding 99% from feedstock to product [1] Company Developments - The achievement represents a significant milestone in the scalability of the eXoZymes platform [1] - eXoZymes is recognized as a pioneer in AI-enhanced enzymes that convert sustainable feedstock into nutraceuticals and new medicines [1]